Celularity Inc

CELUNASDAQ · USD
0.63USD0.00 (-7.99%)
232

Celularity Inc (CELU) Implied Volatility Current

CELU's 30 day implied volatility is 0.01%, with an IV Rank of 0.40%. This is a low IV Rank versus the past year, meaning Celularity Inc options are relatively cheap and currently favor buyers. CELU's 30 day historical volatility sits at 139.48%, which means implied volatility is running 139.47 points below historical volatility, as of Nov 13, 2026.

Read more

Tracking CELU implied volatility helps you spot when Celularity Inc options are historically cheap or expensive, and where the best trades are hiding. When CELU IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor CELU implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking CELU IV rank helps you see whether CELU's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

Implied Volatility

IV Rank
0.40%IV Rank
Low

IV is subdued. Premiums are cheap, favoring buyers.

Implied Volatility (30d)0.01%

IV Rank0.40%

Historical Volatility (30d)139.48%

IV Minus HV-139.47%

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →